TAT-Gap19
TAT-Gap19 Basic information
- Product Name:
- TAT-Gap19
- Synonyms:
-
- TAT-Gap19
- L-Lysine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-glutaminyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl-
- TAT-Gap19 TFA
- L-Tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-glutaminyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl-L-lysine
- CAS:
- 1507930-54-2
- MF:
- C119H212N46O26
- MW:
- 2703.3
- Mol File:
- 1507930-54-2.mol
TAT-Gap19 Chemical Properties
- Density
- 1.46±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- color
- White to off-white
- Water Solubility
- Soluble to 1 mg/ml in water
TAT-Gap19 Usage And Synthesis
Uses
TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice[1][2][3].
Biological Activity
TAT-Gap19 is a cell penetrant analog of a connexin 43 (Cx43) hemichannels selective blocker Gap19. TAT-Gap19 inhibits TAT-Gap19 in mice brain without affecting gap junction channels.
in vivo
A single injection of TAT-Gap19 (i.v. via the tail vein; 55 mg/kg) produces significant immune signal in the brain 24 h later in 4 months old C57Bl6 male mice[1].
TAT-Gap19 (1 mg/kg/day; an osmotic pump implanted in the peritoneal cavity; Two weeks) shows significantly decreased collagen deposition, as well as lowed amounts of α-SMA-positive cells area in mice subjected to treatment with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks[2].
storage
Store at -20°C
References
[1] Verónica Abudara, et al. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014 Oct 21;8:306. DOI:10.3389/fncel.2014.00306
[2] Sara Crespo Yanguas, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3):817. DOI:10.3390/ijms19030817
[3] Laura Walrave, et al. Inhibition of astroglial connexin43 hemichannels with TAT-Gap19 exerts anticonvulsant effects in rodents. Glia. 2018 Aug;66(8):1788-1804. DOI:10.1002/glia.23341
TAT-Gap19Supplier
- Tel
- 0510-85629785 18013409632
- sales@reading-chemicals.com
- Tel
- info@creative-peptides.com
- Tel
- +86-17380623303
- Caroline@youngshechem.com
- Tel
- 0571-87213919
- Eric@peptidego.com
- Tel
- 400-9205774
- sales@glpbio.cn